CAS No.55837-27-9,Piretanide Suppliers

Products Categories

Pharmaceutical (32)
Organic Chemicals (12)
Others (8)
Reagent (2)
Materials (1)

Basic Information

Molecular Structure:
CAS No.:	55837-27-9
Name:	Piretanide
Article Data:	3

Formula:	C₁₇H₁₈N₂O₅S
Molecular Weight:	362.406
Synonyms:	Arelix;Arlix;Diumax;Eurelix;HOE 118;Piretanide;S 73-4118;Tauliz;3-(Aminosulfonyl)-4-phenoxy-5-pyrrolidin-1-ylbenzoic acid;4-Phenoxy-3-pyrrolidin-1-yl-5-sulfamoyl-benzoic acid;
EINECS:	259-852-9
Density:	1.415 g/cm³
Melting Point:	225-227°
Boiling Point:	597.676 °C at 760 mmHg
Flash Point:	315.263 °C
Appearance:	Pale yellow powder.
PSA:	118.31000
LogP:	4.27080

Total:48 Page 1 of 2 1 2 Next>>

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 55837-27-9

Specification

The Piretanide, with the CAS registry number 55837-27-9, is also known as 4-Phenoxy-3-pyrrolidin-1-yl-5-sulfamoyl-benzoic acid. It belongs to the product categories of Amines; Aromatics; Heterocycles; Intermediates & Fine Chemicals; Pharmaceuticals; Sulfur & Selenium Compounds. Its EINECS number is 259-852-9. This chemical's molecular formula is C₁₇H₁₈N₂O₅S and molecular weight is 362.40. What's more, its systematic name is 4-Phenoxy-3-(1-pyrrolidinyl)-5-sulfamoylbenzoic acid. Its classification codes are: (1)Diuretic; (2)Diuretics; (3)Drug / Therapeutic Agent; (4)Membrane Transport Modulators; (5)Natriuretic Agents; (6)Reproductive Effect; (7)Sodium Potassium Chloride Symporter Inhibitors. This chemical has been synthesized in 1973 at Hoechst AG (Germany) as a loop diuretic compound by using a then-new method for introducing cyclic amine residues in an aromatic nucleus in the presence of other aromatically bonded functional groups.

Physical properties of Piretanide are: (1)ACD/LogP: 2.304; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): 0.84; (4)ACD/LogD (pH 7.4): -0.63; (5)ACD/BCF (pH 5.5): 1.15; (6)ACD/BCF (pH 7.4): 1.00; (7)ACD/KOC (pH 5.5): 14.79; (8)ACD/KOC (pH 7.4): 1.00; (9)#H bond acceptors: 7; (10)#H bond donors: 3; (11)#Freely Rotating Bonds: 5; (12)Polar Surface Area: 118.31 Å²; (13)Index of Refraction: 1.64; (14)Molar Refractivity: 92.273 cm³; (15)Molar Volume: 256.028 cm³; (16)Polarizability: 36.58×10^-24cm³; (17)Surface Tension: 63.0 dyne/cm; (18)Density: 1.415 g/cm³; (19)Flash Point: 315.263 °C; (20)Enthalpy of Vaporization: 93.612 kJ/mol; (21)Boiling Point: 597.676 °C at 760 mmHg; (22)Vapour Pressure: 0 mmHg at 25°C.

You can still convert the following datas into molecular structure:
(1)SMILES: O=S(=O)(c2cc(C(=O)O)cc(c2Oc1ccccc1)N3CCCC3)N
(2)Std. InChI: InChI=1S/C17H18N2O5S/c18-25(22,23)15-11-12(17(20)21)10-14(19-8-4-5-9-19)16(15)24-13-6-2-1-3-7-13/h1-3,6-7,10-11H,4-5,8-9H2,(H,20,21)(H2,18,22,23)
(3)Std. InChIKey: UJEWTUDSLQGTOA-UHFFFAOYSA-N

The toxicity data is as follows:

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
dog	LD50	oral	> 1gm/kg (1000mg/kg)		Yakkyoku. Pharmacy. Vol. 35, Pg. 2037, 1984.
guinea pig	LD50	oral	93mg/kg (93mg/kg)		Medicamentos de Actualidad. Vol. 18, Pg. 271, 1982.
mouse	LD50	intraperitoneal	700mg/kg (700mg/kg)	BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES	Kiso to Rinsho. Clinical Report. Vol. 14, Pg. 4254, 1980.
mouse	LD50	intravenous	618mg/kg (618mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: ATAXIA BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)	Kiso to Rinsho. Clinical Report. Vol. 14, Pg. 4254, 1980.
mouse	LD50	oral	2gm/kg (2000mg/kg)	LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE BEHAVIORAL: ATAXIA	Kiso to Rinsho. Clinical Report. Vol. 14, Pg. 4254, 1980.
mouse	LD50	subcutaneous	660mg/kg (660mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: ATAXIA	Kiso to Rinsho. Clinical Report. Vol. 14, Pg. 4254, 1980.
rabbit	LD50	intravenous	178mg/kg (178mg/kg)		Kiso to Rinsho. Clinical Report. Vol. 14, Pg. 4254, 1980.
rabbit	LD50	oral	960mg/kg (960mg/kg)		Kiso to Rinsho. Clinical Report. Vol. 14, Pg. 4254, 1980.
rat	LD50	intraperitoneal	485mg/kg (485mg/kg)	BEHAVIORAL: ATAXIA BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)	Kiso to Rinsho. Clinical Report. Vol. 14, Pg. 4254, 1980.
rat	LD50	intravenous	700mg/kg (700mg/kg)	LUNGS, THORAX, OR RESPIRATION: DYSPNEA BEHAVIORAL: ATAXIA BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)	Kiso to Rinsho. Clinical Report. Vol. 14, Pg. 4254, 1980.
rat	LD50	oral	5601mg/kg (5601mg/kg)		European Journal of Medicinal Chemistry--Chimie Therapeutique. Vol. 11, Pg. 399, 1976.
rat	LD50	subcutaneous	1100mg/kg (1100mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: ATAXIA	Kiso to Rinsho. Clinical Report. Vol. 14, Pg. 4254, 1980.